GLP-1 receptor agonists × body weight & composition

TrialJAMA2021

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.

Domenica Rubino et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 902 people · 2021

Randomised comparison

Probably lowered body weight & composition

−14.8−16.0 to −13.5

As reported

difference −14.8, 95% CI −16.0 to −13.5

One number in the abstract

the abstract, start to end

with the switch to placebo (difference, -14.8 [95% CI, -16.0 to -13.5]

← favours treatmentfavours comparator →
could be chance
Body weight & composition
−14.8−16.0 to −13.5
GLP-1 receptor agonistsBody weight & composition

GLP-1 receptor agonists × body weight & compositionhelps?replicated

unlikelylikely
0.900.90 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

627 papers cite itlatest 60 shown

2021
2025
2026
this paperpooled ittrialcites it

4 trials

Full record →Abstract, authors, funding and every citing paper · PMID 33755728